Marco Rovaris

List of Publications by Citations

Source: https://exaly.com/author-pdf/2246496/marco-rovaris-publications-by-citations.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

270 papers	12,202 citations	62 h-index	99 g-index
277 ext. papers	13,354 ext. citations	5.4 avg, IF	5.6 L-index

#	Paper	IF	Citations
270	Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. *Lancet, The*, **2001**, 357, 1576-82	40	884
269	Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. *Brain*, **2003**, 126, 433-7	11.2	260
268	Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". *Neurology* , **2001**, 57, 731-3	6.5	247
267	MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. *Lancet Neurology, The*, **2007**, 6, 677-86	24.1	246
266	Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. *Lancet, The*, **2008**, 371, 2085-92	40	236
265	Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. *Neurology*, **2010**, 74, 1868-76	6.5	234
264	Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. *Neurology*, **1998**, 50, 1601-8	6.5	230
263	Diffusion MRI in multiple sclerosis. *Neurology*, **2005**, 65, 1526-32	6.5	222
262	Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. *Lancet, The*, **2004**, 364, 1489-96	40	215
261	Secondary progressive multiple sclerosis: current knowledge and future challenges. *Lancet Neurology, The*, **2006**, 5, 343-54	24.1	206
260	MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". *Lancet Neurology, The*, **2006**, 5, 841-52	24.1	194
259	MRI criteria for MS in patients with clinically isolated syndromes. *Neurology*, **2010**, 74, 427-34	6.5	187
258	Cognitive dysfunction in patients with mildly disabling relapsing-remitting multiple sclerosis: an exploratory study with diffusion tensor MR imaging. *Journal of the Neurological Sciences*, **2002**, 195, 103-9	3.2	185
257	Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images. *Journal of Neurology* , **1997**, 244, 266-70	5.5	148
256	Assessment of normal-appearing white and gray matter in patients with primary progressive multiple sclerosis: a diffusion-tensor magnetic resonance imaging study. *Archives of Neurology*, **2002**, 59, 1406-12		148
255	Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2000**, 68, 157-61	5.5	137
254	Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. *Brain*, **2006**, 129, 2620-7	11.2	132

253	Nocturnal sleep study in multiple sclerosis: correlations with clinical and brain magnetic resonance imaging findings. *Journal of the Neurological Sciences*, **1994**, 125, 194-7	3.2	132
252	Magnetization transfer imaging to monitor the evolution of MS: a 1-year follow-up study. *Neurology* , **2000**, 55, 940-6	6.5	130
251	In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. *Brain*, **2001**, 124, 2540-9	11.2	129
250	Age-related changes in conventional, magnetization transfer, and diffusion-tensor MR imaging findings: study with whole-brain tissue histogram analysis. *Radiology*, **2003**, 227, 731-8	20.5	121
249	Multimodal evoked potentials to assess the evolution of multiple sclerosis: a longitudinal study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2006**, 77, 1030-5	5.5	114
248	Whole brain volume changes in patients with progressive MS treated with cladribine. *Neurology*, **2000**, 55, 1714-8	6.5	114
247	Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. *Brain*, **2006**, 129, 2628-34	11.2	111
246	Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. *Brain*, **2001**, 124, 1803-12	11.2	111
245	Mean diffusivity and fractional anisotropy histogram analysis of the cervical cord in MS patients. *NeuroImage*, **2005**, 26, 822-8	7.9	108
244	Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. *Neurology*, **2004**, 62, 1432-4	6.5	106
243	Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. *American Journal of Neuroradiology*, **2005**, 26, 341-6	4.4	106
242	Influence of aging on brain gray and white matter changes assessed by conventional, MT, and DT MRI. *Neurology*, **2006**, 66, 535-9	6.5	101
241	Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI. *NeuroImage*, **2005**, 24, 1139-46	7.9	99
240	Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. *Neurology*, **1997**, 49, 1682-8	6.5	98
239	Diffusion-tensor magnetic resonance imaging detects normal-appearing white matter damage unrelated to short-term disease activity in patients at the earliest clinical stage of multiple sclerosis. *Archives of Neurology*, **2005**, 62, 803-8		97
238	MRI and motor evoked potential findings in nondisabled multiple sclerosis patients with and without symptoms of fatigue. *Journal of Neurology*, **2000**, 247, 506-9	5.5	97
237	A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. *Archives of Neurology*, **2009**, 66, 587-92		96
236	Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. *Annals of Neurology*, **2003**, 53, 718-24	9.4	96

235	Progressive gray matter damage in patients with relapsing-remitting multiple sclerosis: a longitudinal diffusion tensor magnetic resonance imaging study. *Archives of Neurology*, **2005**, 62, 578-84		96
234	A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. *Brain*, **1998**, 121 (Pt 10), 2011-20	11.2	95
233	Fatigue and magnetic resonance imaging activity in multiple sclerosis. *Journal of Neurology*, **1999**, 246, 454-8	5.5	93
232	Quantification of cervical cord pathology in primary progressive MS using diffusion tensor MRI. *Neurology*, **2005**, 64, 631-5	6.5	92
231	Brain involvement in systemic immune mediated diseases: magnetic resonance and magnetisation transfer imaging study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2000**, 68, 170-7	5.5	88
230	Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study. *Brain*, **2003**, 126, 2323-32	11.2	86
229	Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. *Journal of Neurology*, **2013**, 260, 2458-71	5.5	83
228	Predicting progression in primary progressive multiple sclerosis: a 10-year multicenter study. *Annals of Neurology*, **2008**, 63, 790-3	9.4	83
227	Corpus callosum damage and cognitive dysfunction in benign MS. *Human Brain Mapping*, **2009**, 30, 2656-66	5.9	82
226	One year follow up study of primary and transitional progressive multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2000**, 68, 713-8	5.5	82
225	Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. *Multiple Sclerosis Journal*, **2014**, 20, 72-80	5	81
224	Cognitive impairment and structural brain damage in benign multiple sclerosis. *Neurology*, **2008**, 71, 1526-6	6.5	79
223	Electroencephalographic coherence analysis in multiple sclerosis: correlation with clinical, neuropsychological, and MRI findings. *Journal of Neurology, Neurosurgery and Psychiatry*, **2000**, 69, 192-8	5.5	77
222	The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS. *Neurology*, **2003**, 60, 853-60	6.5	76
221	Brain magnetic resonance imaging correlates of cognitive impairment in multiple sclerosis. *Journal of the Neurological Sciences*, **1993**, 115 Suppl, S66-73	3.2	76
220	Magnetization transfer ratios in multiple sclerosis lesions enhancing after different doses of gadolinium. *Neurology*, **1998**, 50, 1289-93	6.5	71
219	Evidence for progressive gray matter loss in patients with relapsing-remitting MS. *Neurology*, **2005**, 65, 1126-8	6.5	69
218	Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease. *Journal of Immunology*, **2009**, 183, 4984-93	5.3	66

217	Intercenter differences in diffusion tensor MRI acquisition. *Journal of Magnetic Resonance Imaging*, **2010**, 31, 1458-68	5.6	66
216	Will Rogers phenomenon in multiple sclerosis. *Annals of Neurology*, **2008**, 64, 428-33	9.4	66
215	Assessment of disease activity in multiple sclerosis phenotypes with combined gadolinium- and superparamagnetic iron oxide-enhanced MR imaging. *Radiology*, **2012**, 264, 225-33	20.5	65
214	Normal-appearing white and grey matter damage in MS. A volumetric and diffusion tensor MRI study at 3.0 Tesla. *Journal of Neurology*, **2007**, 254, 513-8	5.5	65
213	Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study. *Multiple Sclerosis Journal*, **2009**, 15, 36-41	5	64
212	Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. *Multiple Sclerosis Journal*, **2003**, 9, 349-55	5	64
211	Diffusion tensor MR imaging. *Neuroimaging Clinics of North America*, **2009**, 19, 37-43	3	63
210	MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain : A review of reported findings. *Journal of Neurology*, **2008**, 255, 1-10	5.5	63
209	Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 944-51	5.5	63
208	Method for intracellular magnetic labeling of human mononuclear cells using approved iron contrast agents. *Magnetic Resonance Imaging*, **1999**, 17, 1521-3	3.3	62
207	MRI markers of destructive pathology in multiple sclerosis-related cognitive dysfunction. *Journal of the Neurological Sciences*, **2006**, 245, 111-6	3.2	60
206	Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis. *Current Opinion in Neurology*, **1999**, 12, 337-44	7.1	60
205	The effect of cladribine on T(1) ‘black hole’ changes in progressive MS. *Journal of the Neurological Sciences*, **2000**, 176, 42-4	3.2	58
204	MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. *Nature Reviews Neurology*, **2011**, 8, 13-21	15	57
203	Relative contributions of brain and cervical cord pathology to multiple sclerosis disability: a study with magnetisation transfer ratio histogram analysis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2000**, 69, 723-7	5.5	56
202	Indoleamine 2,3 Dioxygenase (IDO) Expression and Activity in Relapsing-Remitting Multiple Sclerosis. *PLoS ONE*, **2015**, 10, e0130715	3.7	55
201	A magnetic resonance imaging voxel-based morphometry study of regional gray matter atrophy in patients with benign multiple sclerosis. *Archives of Neurology*, **2008**, 65, 1223-30		54
200	Magnetic resonance imaging, magnetisation transfer imaging, and diffusion weighted imaging correlates of optic nerve, brain, and cervical cord damage in Leber’s hereditary optic neuropathy. *Journal of Neurology, Neurosurgery and Psychiatry*, **2001**, 70, 444-9	5.5	53

199	Diffusion tensor MRI in multiple sclerosis. *Journal of Neuroimaging*, **2007**, 17 Suppl 1, 27S-30S	2.8	52
198	Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data. *Neurology*, **2005**, 65, 633-5	6.5	52
197	Correlations between clinical findings and magnetization transfer imaging metrics of tissue damage in individuals with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. *Stroke*, **2001**, 32, 643-8	6.7	52
196	Delivery to the central nervous system of a nonreplicative herpes simplex type 1 vector engineered with the interleukin 4 gene protects rhesus monkeys from hyperacute autoimmune encephalomyelitis. *Human Gene Therapy*, **2001**, 12, 905-20	4.8	52
195	Morphology and evolution of cortical lesions in multiple sclerosis. A longitudinal MRI study. *NeuroImage*, **2008**, 42, 1324-8	7.9	51
194	Mitoxantrone for multiple sclerosis. *The Cochrane Library*, **2013**, CD002127	5.2	46
193	Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. *Multiple Sclerosis Journal*, **2008**, 14, 455-64	5	46
192	Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis. *Journal of Neurology*, **2000**, 247, 960-5	5.5	46
191	Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial. *Multiple Sclerosis Journal*, **2007**, 13, 502-8	5	45
190	Occult tissue damage in patients with primary progressive multiple sclerosis is independent of T2-visible lesions--a diffusion tensor MR study. *Journal of Neurology*, **2003**, 250, 456-60	5.5	45
189	Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution. *Neurology*, **2005**, 65, 1626-30	6.5	45
188	Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets. *Journal of Neurology, Neurosurgery and Psychiatry*, **2001**, 70, 494-9	5.5	45
187	T helper-17 activation dominates the immunologic milieu of both amyotrophic lateral sclerosis and progressive multiple sclerosis. *Clinical Immunology*, **2013**, 148, 79-88	9	44
186	Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study. *Archives of Neurology*, **2007**, 64, 1163-8		44
185	A high-resolution three-dimensional T1-weighted gradient echo sequence improves the detection of disease activity in multiple sclerosis. *Annals of Neurology*, **1996**, 40, 901-7	9.4	44
184	Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. *BMC Neurology*, **2014**, 14, 65	3.1	43
183	MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype. *Neurology*, **2009**, 72, 1693-701	6.5	43
182	Impaired short-term motor learning in multiple sclerosis: evidence from virtual reality. *Neurorehabilitation and Neural Repair*, **2007**, 21, 273-8	4.7	42

181	The Italian multiple sclerosis register. *Neurological Sciences*, **2019**, 40, 155-165	3.5	42
180	Interferon beta for secondary progressive multiple sclerosis. *The Cochrane Library*, **2012**, 1, CD005181	5.2	41
179	T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2011**, 82, 72-7	5.5	41
178	Effects of motor rehabilitation on mobility and brain plasticity in multiple sclerosis: a structural and functional MRI study. *Journal of Neurology*, **2018**, 265, 1393-1401	5.5	40
177	Whole-brain atrophy in multiple sclerosis measured by two segmentation processes from various MRI sequences. *Journal of the Neurological Sciences*, **2003**, 216, 169-77	3.2	40
176	Review neuroimaging in amyotrophic lateral sclerosis. *European Journal of Neurology*, **1999**, 6, 629-37	6	40
175	A multiparametric MRI study of frontal lobe dementia in multiple sclerosis. *Journal of the Neurological Sciences*, **1999**, 171, 135-44	3.2	40
174	Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: a longitudinal study. *Multiple Sclerosis Journal*, **2014**, 20, 1900-3	5	39
173	Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment. *Journal of Immunology Research*, **2014**, 2014, 961863	4.5	39
172	Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS. *Neurology*, **2007**, 68, 939-44	6.5	39
171	Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually-edited SIENA and SIENAX. *Journal of Magnetic Resonance Imaging*, **2007**, 26, 881-5	5.6	39
170	An MT MRI study of the cervical cord in clinically isolated syndromes suggestive of MS. *Neurology*, **2004**, 63, 584-5	6.5	39
169	Long-term disability progression in primary progressive multiple sclerosis: a 15-year study. *Brain*, **2017**, 140, 2814-2819	11.2	38
168	Interferon for secondary progressive multiple sclerosis: a systematic review. *Journal of Neurology, Neurosurgery and Psychiatry*, **2013**, 84, 420-6	5.5	38
167	Two-year follow-up study of primary and transitional progressive multiple sclerosis. *Multiple Sclerosis Journal*, **2002**, 8, 108-14	5	38
166	Immunological patterns identifying disease course and evolution in multiple sclerosis patients. *Journal of Neuroimmunology*, **2005**, 165, 192-200	3.5	36
165	A diffusion tensor MRI study of cervical cord damage in benign and secondary progressive multiple sclerosis patients. *Journal of Neurology, Neurosurgery and Psychiatry*, **2010**, 81, 26-30	5.5	34
164	A 3-year diffusion tensor MRI study of grey matter damage progression during the earliest clinical stage of MS. *Journal of Neurology*, **2008**, 255, 1209-14	5.5	34

163	A reassessment of the plateauing relationship between T2 lesion load and disability in MS. *Neurology*, **2009**, 73, 1538-42	6.5	32
162	Frequency and patterns of subclinical cognitive impairment in patients with ANCA-associated small vessel vasculitides. *Journal of the Neurological Sciences*, **2002**, 195, 161-6	3.2	31
161	Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups. *Journal of Neurology*, **1996**, 243, 536-42	5.5	31
160	Axonal injury and overall tissue loss are not related in primary progressive multiple sclerosis. *Archives of Neurology*, **2005**, 62, 898-902		30
159	Online meditation training for people with multiple sclerosis: A randomized controlled trial. *Multiple Sclerosis Journal*, **2019**, 25, 610-617	5	30
158	MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression. *Journal of Translational Medicine*, **2015**, 13, 148	8.5	29
157	Corticospinal tract integrity is related to primary motor cortex thinning in relapsing-remitting multiple sclerosis. *Multiple Sclerosis Journal*, **2015**, 21, 1771-80	5	29
156	Are Modular Activations Altered in Lower Limb Muscles of Persons with Multiple Sclerosis during Walking? Evidence from Muscle Synergies and Biomechanical Analysis. *Frontiers in Human Neuroscience*, **2016**, 10, 620	3.3	29
155	Integrated telerehabilitation approach in multiple sclerosis: A systematic review and meta-analysis. *Journal of Telemedicine and Telecare*, **2020**, 26, 385-399	6.8	29
154	A longitudinal magnetic resonance imaging study of the cervical cord in multiple sclerosis **1997**, 7, 78-80		28
153	Mitoxantrone for multiple sclerosis. *Cochrane Database of Systematic Reviews*, **2005**, CD002127		28
152	An MR study of tissue damage in the cervical cord of patients with migraine. *Journal of the Neurological Sciences*, **2001**, 183, 43-6	3.2	28
151	B Lymphocytes in Multiple Sclerosis: Bregs and BTLA/CD272 Expressing-CD19+ Lymphocytes Modulate Disease Severity. *Scientific Reports*, **2016**, 6, 29699	4.9	28
150	Longitudinal associations between mindfulness and well-being in people with multiple sclerosis. *International Journal of Clinical and Health Psychology*, **2019**, 19, 22-30	5.1	28
149	Prediction of Falls in Subjects Suffering From Parkinson Disease, Multiple Sclerosis, and Stroke. *Archives of Physical Medicine and Rehabilitation*, **2018**, 99, 641-651	2.8	27
148	A composite score to predict short-term disease activity in patients with relapsing-remitting MS. *Neurology*, **2007**, 69, 1230-5	6.5	27
147	Somatosensory evoked potentials and sensory involvement in multiple sclerosis: comparison with clinical findings and quantitative sensory tests. *Multiple Sclerosis Journal*, **2003**, 9, 275-9	5	27
146	Effects of seasons on magnetic resonance imaging measured disease activity in patients with multiple sclerosis. *Annals of Neurology*, **2001**, 49, 415-416	9.4	27

145	Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study. *Journal of Neurology*, **2018**, 265, 1850-1859	5.5	27
144	Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. *Multiple Sclerosis Journal*, **2009**, 15, 1459-65	5	26
143	Semi-automated thresholding technique for measuring lesion volumes in multiple sclerosis: effects of the change of the threshold on the computed lesion loads. *Acta Neurologica Scandinavica*, **1996**, 93, 30-4	3.8	26
142	Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. *The Cochrane Library*, **2016**, 11, CD009333	5.2	25
141	Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses. *Neurology*, **2002**, 59, 1429-32	6.5	25
140	Brain MRI correlates of magnetization transfer imaging metrics in patients with multiple sclerosis. *Journal of the Neurological Sciences*, **1999**, 166, 58-63	3.2	25
139	Acute myelopathy of unknown aetiology: a clinical, neurophysiological and MRI study of short- and long-term prognostic factors. *Journal of Neurology*, **1995**, 242, 497-503	5.5	25
138	Brain stem magnetic resonance imaging and evoked potential studies of symptomatic multiple sclerosis patients. *European Neurology*, **1993**, 33, 232-7	2.1	25
137	A role for the TIM-3/GAL-9/BAT3 pathway in determining the clinical phenotype of multiple sclerosis. *FASEB Journal*, **2014**, 28, 5000-9	0.9	23
136	A comparison of conventional and fast spin-echo sequences for the measurement of lesion load in multiple sclerosis using a semi-automated contour technique. *Neuroradiology*, **1997**, 39, 161-5	3.2	23
135	Magnetic resonance imaging of multiple sclerosis. *Journal of Neuroimaging*, **2002**, 12, 289-301	2.8	23
134	A simple and universal enzyme-free approach for the detection of multiple microRNAs using a single nanostructured enhancer of surface plasmon resonance imaging. *Analytical and Bioanalytical Chemistry*, **2019**, 411, 1873-1885	4.4	23
133	Intensive Multimodal Training to Improve Gait Resistance, Mobility, Balance and Cognitive Function in Persons With Multiple Sclerosis: A Pilot Randomized Controlled Trial. *Frontiers in Neurology*, **2018** , 9, 800	4.1	23
132	Imaging primary progressive multiple sclerosis: the contribution of structural, metabolic, and functional MRI techniques. *Multiple Sclerosis Journal*, **2004**, 10 Suppl 1, S36-44; discussion S44-5	5	22
131	Monosodium Urate Crystals Activate the Inflammasome in Primary Progressive Multiple Sclerosis. *Frontiers in Immunology*, **2018**, 9, 983	8.4	21
130	DTI parameter optimisation for acquisition at 1.5T: SNR analysis and clinical application. *Computational Intelligence and Neuroscience*, **2010**, 254032	3	21
129	In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis. *Multiple Sclerosis Journal*, **2009**, 15, 789-94	5	21
128	Quantitative brain volumetric analysis from patients with multiple sclerosis: a follow-up study. *Journal of the Neurological Sciences*, **1999**, 171, 8-10	3.2	21

127	Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study). *PLoS ONE*, **2017**, 12, e0180651	3.7	20
126	HLA alleles modulate EBV viral load in multiple sclerosis. *Journal of Translational Medicine*, **2018**, 16, 80	8.5	20
125	A novel data mining system points out hidden relationships between immunological markers in multiple sclerosis. *Immunity and Ageing*, **2013**, 10, 1	9.7	20
124	Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis. *American Journal of Neuroradiology*, **2003**, 24, 75-81	4.4	20
123	Fingolimod effects on left ventricular function in multiple sclerosis. *Multiple Sclerosis Journal*, **2016**, 22, 201-11	5	19
122	Incorporating domain knowledge into the fuzzy connectedness framework: application to brain lesion volume estimation in multiple sclerosis. *IEEE Transactions on Medical Imaging*, **2007**, 26, 1670-80	11.7	19
121	Movement preparation is affected by tissue damage in multiple sclerosis: evidence from EEG event-related desynchronization. *Clinical Neurophysiology*, **2005**, 116, 1515-9	4.3	19
120	The contribution of fast-FLAIR MRI for lesion detection in the brain of patients with systemic autoimmune diseases. *Journal of Neurology*, **2000**, 247, 29-33	5.5	19
119	Cervical cord magnetic resonance imaging findings in systemic immune-mediated diseases. *Journal of the Neurological Sciences*, **2000**, 176, 128-30	3.2	19
118	Cardiac autonomic function during sleep and wakefulness in multiple sclerosis. *Journal of Neurology*, **1995**, 242, 639-43	5.5	19
117	Insights from magnetic resonance imaging. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2014**, 122, 115-49	3	18
116	Agreement between different input image types in brain atrophy measurement in multiple sclerosis using SIENAX and SIENA. *Journal of Magnetic Resonance Imaging*, **2008**, 28, 559-65	5.6	18
115	A diffusion tensor MRI study of basal ganglia from patients with ADEM. *Journal of the Neurological Sciences*, **2003**, 206, 27-30	3.2	18
114	The value of new magnetic resonance techniques in multiple sclerosis. *Current Opinion in Neurology* , **2000**, 13, 249-54	7.1	18
113	Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. *Neurological Sciences*, **2013**, 34, 1633-7	3.5	17
112	A comparison of the sensitivity of MRI after double- and triple-dose Gd-DTPA for detecting enhancing lesions in multiple sclerosis. *Magnetic Resonance Imaging*, **2000**, 18, 761-3	3.3	17
111	Assessment of the damage of the cerebral hemispheres in MS using neuroimaging techniques. *Journal of the Neurological Sciences*, **2000**, 172 Suppl 1, S63-6	3.2	17
110	Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology. *Journal of Neurology, Neurosurgery and Psychiatry*, **1999**, 67, 386-9	5.5	17

109	Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. *Cochrane Database of Systematic Reviews*, **2014**, CD009333		16
108	JC virus detection and JC virus-specific immunity in natalizumab-treated multiple sclerosis patients. *Journal of Translational Medicine*, **2012**, 10, 248	8.5	16
107	The effect of repositioning on brain MRI lesion load assessment in multiple sclerosis: reliability of subjective quality criteria. *Journal of Neurology*, **1998**, 245, 273-5	5.5	16
106	Serial whole-brain N-acetylaspartate concentration in healthy young adults. *American Journal of Neuroradiology*, **2007**, 28, 1650-1	4.4	16
105	White Matter Tract Injury is Associated with Deep Gray Matter Iron Deposition in Multiple Sclerosis. *Journal of Neuroimaging*, **2017**, 27, 107-113	2.8	15
104	Drug therapy for multiple sclerosis. *Cmaj*, **2014**, 186, 833-40	3.5	15
103	Modulation of the central memory and Tr1-like regulatory T cells in multiple sclerosis patients responsive to interferon-beta therapy. *Multiple Sclerosis Journal*, **2012**, 18, 788-98	5	15
102	Sensitivity and reproducibility of fast-FLAIR, FSE, and TGSE sequences for the MRI assessment of brain lesion load in multiple sclerosis: a preliminary study **1997**, 7, 98-102		15
101	A brain magnetization transfer MRI study with a clinical follow up of about four years in patients with clinically isolated syndromes suggestive of multiple sclerosis. *Journal of Neurology*, **2007**, 254, 78-83	5.5	15
100	The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials. *Multiple Sclerosis Journal*, **2004**, 10, 341-7	5	15
99	Sample size estimations for MRI-monitored trials of MS comparing new vs standard treatments. *Neurology*, **2001**, 57, 1883-5	6.5	15
98	Adverse events after endovascular treatment of chronic cerebro-spinal venous insufficiency (CCSVI) in patients with multiple sclerosis. *Multiple Sclerosis Journal*, **2013**, 19, 961-3	5	14
97	Opposite effects of interferon-β on new B and T cell release from production sites in multiple sclerosis patients. *Journal of Neuroimmunology*, **2011**, 240-241, 147-50	3.5	13
96	Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?. *Multiple Sclerosis Journal*, **2009**, 15, 465-71	5	13
95	Absence of diffuse cervical cord tissue damage in early, non-disabling relapsing-remitting MS: a preliminary study. *Multiple Sclerosis Journal*, **2008**, 14, 853-6	5	13
94	Beta endorphin concentrations in PBMC of patients with different clinical phenotypes of multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2003**, 74, 495-7	5.5	13
93	Diffusion tensor MRI of the cervical cord in a patient with syringomyelia and multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2004**, 75, 1647	5.5	13
92	Differential diagnosis of posterior fossa multiple sclerosis lesions--neuroradiological aspects. *Neurological Sciences*, **2001**, 22 Suppl 2, S79-83	3.5	13

91	A preliminary study comparing the sensitivity of serial monthly enhanced MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in primary progressive multiple sclerosis **1998**, 8, 88-93		13
90	Lesion load quantification on fast-FLAIR, rapid acquisition relaxation-enhanced, and gradient spin echo brain MRI scans from multiple sclerosis patients. *Magnetic Resonance Imaging*, **1999**, 17, 1105-10	3.3	13
89	Short-term evolution of new multiple sclerosis lesions enhancing on standard and triple dose gadolinium-enhanced brain MRI scans. *Journal of the Neurological Sciences*, **1999**, 164, 148-52	3.2	13
88	Cumulative effect of a weekly low dose of interferon beta 1a on standard and triple dose contrast-enhanced MRI from multiple sclerosis patients. *Journal of the Neurological Sciences*, **1999**, 171, 130-4	3.2	13
87	Comparative efficacy of interferon versus glatiramer acetate for relapsing-remitting multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 1016-20	5.5	12
86	Determinants of disability in multiple sclerosis: an immunological and MRI study. *BioMed Research International*, **2014**, 2014, 875768	3	12
85	Interventions for the prevention of brain atrophy in multiple sclerosis : current status. *CNS Drugs*, **2003**, 17, 563-75	6.7	12
84	Contribution of cervical cord MRI and brain magnetization transfer imaging to the assessment of individual patients with multiple sclerosis: a preliminary study. *Multiple Sclerosis Journal*, **2002**, 8, 52-8	5	12
83	The Effects of Transcutaneous Spinal Direct Current Stimulation on Neuropathic Pain in Multiple Sclerosis: Clinical and Neurophysiological Assessment. *Frontiers in Human Neuroscience*, **2019**, 13, 31	3.3	11
82	Grey matter damage in progressive multiple sclerosis versus amyotrophic lateral sclerosis: a voxel-based morphometry MRI study. *Neurological Sciences*, **2015**, 36, 371-7	3.5	11
81	A telemedicine meditation intervention for people with multiple sclerosis and their caregivers: study protocol for a randomized controlled trial. *Trials*, **2016**, 17, 4	2.8	11
80	Toll-like receptor 3 differently modulates inflammation in progressive or benign multiple sclerosis. *Clinical Immunology*, **2014**, 150, 109-20	9	11
79	MRI evolution of new MS lesions enhancing after different doses of gadolinium. *Acta Neurologica Scandinavica*, **1998**, 98, 90-3	3.8	11
78	Magnetic resonance-based techniques for the study and management of multiple sclerosis. *British Medical Bulletin*, **2003**, 65, 133-44	5.4	11
77	Clinical and MRI assessment of brain damage in MS. *Neurological Sciences*, **2001**, 22 Suppl 2, S123-7	3.5	11
76	The role of non-conventional MR techniques to study multiple sclerosis patients. *Journal of the Neurological Sciences*, **2001**, 186 Suppl 1, S3-9	3.2	11
75	Correlation between MRI and short-term clinical activity in multiple sclerosis: comparison between standard- and triple-dose Gd-enhanced MRI. *European Neurology*, **1999**, 41, 123-7	2.1	10
74	Multiple sclerosis: interobserver agreement in reporting active lesions on serial brain MRI using conventional spin echo, fast spin echo, fast fluid-attenuated inversion recovery and post-contrast T1-weighted images. *Journal of Neurology*, **1999**, 246, 920-5	5.5	10

73	Predictors of effectiveness of multidisciplinary rehabilitation treatment on motor dysfunction in multiple sclerosis. *Multiple Sclerosis Journal*, **2014**, 20, 862-70	5	9
72	Anton's syndrome following callosal disconnection. *Behavioural Neurology*, **2007**, 18, 183-6	3	9
71	A longitudinal brain MRI study comparing the sensitivities of the conventional and a newer approach for detecting active lesions in multiple sclerosis. *Journal of the Neurological Sciences*, **1998**, 159, 94-101	3.2	9
70	Reproducibility of brain MRI lesion volume measurements in multiple sclerosis using a local thresholding technique: effects of formal operator training. *European Neurology*, **1999**, 41, 226-30	2.1	9
69	A new method for analyzing histograms of brain magnetization transfer ratios: comparison with existing techniques. *American Journal of Neuroradiology*, **2004**, 25, 1234-41	4.4	9
68	Italian consensus on treatment of spasticity in multiple sclerosis. *European Journal of Neurology*, **2020**, 27, 445-453	6	9
67	Relationship between brain MRI lesion load and short-term disease evolution in non-disabling MS: a large-scale, multicentre study. *Multiple Sclerosis Journal*, **2011**, 17, 319-26	5	8
66	Magnetization transfer and diffusion tensor MR imaging of the optic radiations and calcarine cortex from patients with Leber's hereditary optic neuropathy. *Journal of the Neurological Sciences*, **2001**, 188, 33-6	3.2	8
65	Signal-to-noise ratio of diffusion weighted magnetic resonance imaging: Estimation methods and in vivo application to spinal cord. *Biomedical Signal Processing and Control*, **2012**, 7, 285-294	4.9	7
64	Can glatiramer acetate reduce brain atrophy development in multiple sclerosis?. *Journal of the Neurological Sciences*, **2005**, 233, 139-43	3.2	7
63	Defining the response to multiple sclerosis treatment: the role of conventional magnetic resonance imaging. *Neurological Sciences*, **2005**, 26 Suppl 4, S204-8	3.5	7
62	A comparison between the sensitivities of 3-mm and 5-mm thick serial brain MRI for detecting lesion volume changes in patients with multiple sclerosis **1998**, 8, 144-7		7
61	Correlation between enhancing lesion number and volume on standard and triple dose gadolinium-enhanced brain MRI scans from patients with multiple sclerosis. *Magnetic Resonance Imaging*, **1999**, 17, 985-8	3.3	7
60	A comparison of the sensitivity of monthly unenhanced and enhanced MRI techniques in detecting new multiple sclerosis lesions. *Journal of Neurology*, **1999**, 246, 97-106	5.5	7
59	Pattern visual evoked potential mapping in Alzheimer's disease: correlations with visuospatial impairment. *Dementia and Geriatric Cognitive Disorders*, **1996**, 7, 63-8	2.6	7
58	Mindfulness-Based Interventions for the Improvement of Well-Being in People With Multiple Sclerosis: A Systematic Review and Meta-Analysis. *Psychosomatic Medicine*, **2020**, 82, 600-613	3.7	7
57	A Deficit of CEACAM-1-Expressing T Lymphocytes Supports Inflammation in Primary Progressive Multiple Sclerosis. *Journal of Immunology*, **2019**, 203, 76-83	5.3	6
56	TH17-Driven Inflammation is Present in All Clinical Forms of Multiple Sclerosis; Disease Quiescence is Associated with Gata3-Expressing Cells. *European Journal of Inflammation*, **2013**, 11, 223-235	0.3	6

55	Clinical trials and clinical practice in multiple sclerosis: conventional and emerging magnetic resonance imaging technologies. *Current Neurology and Neuroscience Reports*, **2002**, 2, 267-76	6.6	6
54	The role of magnetic resonance in the assessment of multiple sclerosis. *Journal of the Neurological Sciences*, **2000**, 172 Suppl 1, S3-S12	3.2	6
53	Modelling new enhancing MRI lesion counts in multiple sclerosis. *Multiple Sclerosis Journal*, **2001**, 7, 298-304	3	6
52	Social Cognition Training for Enhancing Affective and Cognitive Theory of Mind in Schizophrenia: A Systematic Review and a Meta-Analysis. *Journal of Psychology: Interdisciplinary and Applied*, **2021**, 155, 26-58	2.7	6
51	Indoleamine-2,3-dioxygenase(IDO)2 polymorphisms are not associated with multiple sclerosis in Italians. *Journal of the Neurological Sciences*, **2017**, 377, 31-34	3.2	5
50	Assessing balance in non-disabled subjects with multiple sclerosis: Validation of the Fullerton Advanced Balance Scale. *Multiple Sclerosis and Related Disorders*, **2020**, 42, 102085	4	5
49	6-Month Effects of Fingolimod on Indexes of Cardiovascular Autonomic Control in Multiple Sclerosis. *Journal of the American College of Cardiology*, **2016**, 68, 2027-2029	15.1	5
48	Assessing "occult" cervical cord damage in patients with neuropsychiatric systemic lupus erythematosus using diffusion tensor MRI. *Journal of Neurology, Neurosurgery and Psychiatry*, **2007**, 78, 893-5	5.5	5
47	"Importance sampling": a strategy to overcome the clinical/MRI paradox in MS?. *Journal of the Neurological Sciences*, **2005**, 237, 1-3	3.2	5
46	Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". *Neurology* , **2002**, 58, 1440-1; author reply 1441-2	6.5	5
45	Prevalence and patterns of subclinical motor and cognitive impairments in non-disabled individuals with early multiple sclerosis: A multicenter cross-sectional study. *Annals of Physical and Rehabilitation Medicine*, **2021**, 65, 101491	3.8	5
44	Acute Fingolimod Effects on Baroreflex and Cardiovascular Autonomic Control in Multiple Sclerosis. *Journal of Central Nervous System Disease*, **2019**, 11, 1179573519849945	4.4	4
43	Atlas-based versus individual-based fiber tracking of the corpus callosum in patients with multiple sclerosis: reliability and clinical correlations. *Journal of Neuroimaging*, **2012**, 22, 355-64	2.8	4
42	Effect of arm cycling and task-oriented exercises on fatigue and upper limb performance in multiple sclerosis: a randomized crossover study. *International Journal of Rehabilitation Research*, **2019**, 42, 300-308	1.8	4
41	MR-based technology for in vivo detection, characterization, and quantification of pathology of relapsing-remitting multiple sclerosis. *Journal of Rehabilitation Research and Development*, **2002**, 39, 243-59		4
40	A semi-automated measuring system of brain diffusion and perfusion magnetic resonance imaging abnormalities in patients with multiple sclerosis based on the integration of coregistration and tissue segmentation procedures. *BMC Medical Imaging*, **2016**, 16, 4	2.9	3
39	The still under-investigated role of cognitive deficits in PML diagnosis. *Multiple Sclerosis and Demyelinating Disorders*, **2017**, 2,	0	3
38	The Peripheral Network between Oxidative Stress and Inflammation in Multiple Sclerosis. *European Journal of Inflammation*, **2014**, 12, 351-363	0.3	3

37	How does brain MRI lesion volume change on serial scans in patients with multiple sclerosis?. *Magnetic Resonance Imaging*, **1998**, 16, 1181-3	3.3	3
36	Brain MRI lesion volume measurement reproducibility is not dependent on the disease burden in patients with multiple sclerosis. *Magnetic Resonance Imaging*, **1998**, 16, 1185-9	3.3	3
35	The definition of non-responder to multiple sclerosis treatment: neuroimaging markers. *Neurological Sciences*, **2008**, 29 Suppl 2, S222-4	3.5	3
34	Glatiramer acetate in multiple sclerosis. *Expert Review of Neurotherapeutics*, **2005**, 5, 451-8	4.3	3
33	Neuroimaging techniques in the diagnostic work-up of patients with the antiphospholipid syndrome. *Current Rheumatology Reports*, **2001**, 3, 301-6	4.9	3
32	Detection of multiple sclerosis lesions using EPI-FLAIR images. *Magnetic Resonance Imaging*, **2000**, 18, 907-10	3.3	3
31	Detecting new lesion formation in multiple sclerosis: the relative contributions of monthly dual-echo and T1-weighted scans after triple-dose gadolinium. *European Neurology*, **1998**, 40, 146-50	2.1	3
30	A longitudinal study comparing the sensitivity of CSE and RARE sequences in detecting new multiple sclerosis lesions. *Magnetic Resonance Imaging*, **1999**, 17, 457-8	3.3	3
29	Diagnostic tools for assessment of urinary dysfunction in MS patients without urinary disturbances. *Neurological Sciences*, **2016**, 37, 437-42	3.5	2
28	EEG correlates of cognitive impairment in MS. *Italian Journal of Neurological Sciences*, **1998**, 19, S413-S417		2
27	Brain MRI follow-up of patients with persistent isolated optic neuritis. *European Journal of Neurology*, **1996**, 3, 36-39	6	2
26	Intra-observer, inter-observer and inter-scanner variations in brain MRI volume measurements in multiple sclerosis. *Multiple Sclerosis Journal*, **2001**, 7, 27-31	5	2
25	Neuroplasticity and Motor Rehabilitation in Multiple Sclerosis: A Systematic Review on MRI Markers of Functional and Structural Changes. *Frontiers in Neuroscience*, **2021**, 15, 707675	5.1	2
24	Improved Gait of Persons With Multiple Sclerosis After Rehabilitation: Effects on Lower Limb Muscle Synergies, Push-Off, and Toe-Clearance. *Frontiers in Neurology*, **2020**, 11, 668	4.1	2
23	Cardiac autonomic function during postural changes and exercise in people with multiple sclerosis: A cross-sectional study. *Multiple Sclerosis and Related Disorders*, **2018**, 24, 85-90	4	2
22	Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. *Journal of Neurology*, **2019**, 266, 3098-3107	5.5	1
21	Predictors of hospital-based multidisciplinary rehabilitation effects in persons with multiple sclerosis: a large-scale, single-centre study. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2019**, 5, 2055217319843673	2	1
20	The IN-DEEP project "INtegrating and Deriving Evidence, Experiences, Preferences": a web information model on magnetic resonance imaging for people with multiple sclerosis. *Journal of Neurology*, **2020**, 267, 2421-2431	5.5	1

19	Modular organization of lower limbs in persons with multiple sclerosis and healthy persons during walking. *Gait and Posture*, **2015**, 42, S14-S15	2.6	1
18	Multidisciplinary Rehabilitation is Efficacious and Induces Neural Plasticity in Multiple Sclerosis even when Complicated by Progressive Multifocal Leukoencephalopathy. *Frontiers in Neurology*, **2017**, 8, 491	4.1	1
17	Atlas-based vs. individual-based deterministic tractography of corpus callosum in multiple sclerosis. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*, **2009**, 2009, 2699-702	0.9	1
16	Walking With Horizontal Head Turns Is Impaired in Persons With Early-Stage Multiple Sclerosis Showing Normal Locomotion.. *Frontiers in Neurology*, **2021**, 12, 821640	4.1	1
15	Effects of home-based virtual reality telerehabilitation system in people with multiple sclerosis: A randomized controlled trial. *Journal of Telemedicine and Telecare*, **2021**, 1357633X211054839	6.8	1
14	Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 914-920	5.5	1
13	Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. *Multiple Sclerosis Journal*, **2021**, 27, 430-438	5	1
12	Impaired heart rate recovery after sub-maximal physical exercise in people with multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2020**, 40, 101960	4	0
11	Response to Letter "Prediction of Falls in Subjects Suffering From Parkinson Disease, Multiple Sclerosis, and Stroke: Methodologic Issues". *Archives of Physical Medicine and Rehabilitation*, **2018**, 99, 1688-1689	2.8	0
10	The influence of slice orientation on brain MRI lesion load measurement in multiple sclerosis. *Multiple Sclerosis Journal*, **1997**, 3, 382-4	5	0
9	Effects of voice rehabilitation in people with MS: A double-blinded long-term randomized controlled trial. *Multiple Sclerosis Journal*, **2021**, 13524585211051059	5	0
8	Physical activity in non-disabled People with early Multiple Sclerosis: a multicenter cross-sectional study. *Multiple Sclerosis and Related Disorders*, **2022**, 103941	4	0
7	Response to letter regarding article Œingolimod effects on left ventricular function in multiple sclerosisQ*Multiple Sclerosis Journal*, **2016**, 22, 708-9	5	
6	Diffusion and perfusion MRI in inflammation and demyelination488-500		
5	Diffusion imaging in demyelination and inflammation **2004**, 444-459		
4	A theory of mind training for people with multiple sclerosis: Development of a scale to assess the treatment acceptability. *Current Psychology*,1	1.4	
3	Diffusion-Weighted Imaging **2007**, 65-74		
2	White Matter Pathology in Systemic Immune-Mediated Diseases **2005**, 343-352		

1 Magnetic resonance imaging to study white matter damage in multiple sclerosis79-85